What is the main purpose of this 8-K filing?

This 8-K filing announces Amgen Inc.'s definitive agreement to acquire Immunex Corporation. It outlines the key terms of the merger, including the consideration to be paid to Immunex shareholders and the conditions for closing the transaction.

How will Immunex shareholders be compensated for their shares?

Immunex shareholders will receive 0.440 shares of Amgen common stock and $4.50 in cash for each share of Immunex common stock they hold, excluding any dissenting shares.

What is the role of American Home Products Corporation (AHP) in this deal?

AHP, which beneficially owns approximately 41% of Immunex's outstanding shares, has entered into a Shareholder Voting Agreement with Amgen. AHP has agreed to vote its Immunex shares in favor of the merger and has granted Amgen an irrevocable proxy to vote these shares for the transaction.

Are there any conditions that need to be met for the merger to be completed?

Yes, the completion of the merger is subject to several conditions, including the approval of the merger by a majority of Amgen's stockholders, the approval by a majority of Immunex's shareholders, and the satisfactory expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

AMGN 8-K SEC Disclosure

Summary

Amgen Inc. (AMGN) has filed an 8-K report on December 17, 2001, detailing a significant corporate development: an Agreement and Plan of Merger with Immunex Corporation. This strategic move involves Amgen acquiring Immunex through its wholly-owned subsidiary, AMS Acquisition Inc. The transaction is structured as a reverse merger where AMS will merge into Immunex, with Immunex surviving as a subsidiary of Amgen. This acquisition is poised to be a major step for Amgen, likely expanding its product pipeline and market presence, particularly in areas where Immunex has strength. The financial terms involve a stock-and-cash consideration for Immunex shareholders, with each share of Immunex common stock (excluding dissenting shares) being exchanged for 0.440 shares of Amgen common stock and $4.50 in cash. The deal's completion is contingent upon customary conditions, including shareholder approvals from both companies and regulatory clearance under the Hart-Scott-Rodino Act, indicating a thorough vetting process.

Key Highlights

1Amgen Inc. entered into an Agreement and Plan of Merger with Immunex Corporation on December 16, 2001.
2The acquisition will be completed through Amgen's subsidiary, AMS Acquisition Inc., merging with and into Immunex, making Immunex a wholly-owned subsidiary of Amgen.
3Immunex shareholders will receive 0.440 shares of Amgen common stock and $4.50 in cash for each share of Immunex common stock (excluding dissenting shares).
4Amgen will assume outstanding stock options from Immunex, converting them into options to acquire Amgen common stock, with adjustments for certain options.
5The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
6American Home Products Corporation (AHP) and its subsidiaries, collectively owning approximately 41% of Immunex, have entered into a Voting Agreement to support the merger.
7The transaction is subject to the approval of Amgen and Immunex shareholders, as well as the expiration of the Hart-Scott-Rodino antitrust waiting period.

AMGEN INC 8-K Report (Dec 17, 2001)

Summary

Key Highlights

Frequently Asked Questions